NR3C2 and hydrops fetalis: Evaluating the prevalence and significance of hyperkalemia in HF patients is essential for optimizing the use of potassium sparing agents, such the renin–angiotensin–aldosterone system inhibitors (RAASi) or angiotensin receptor‐neprilysin inhibitors and mineralocorticoid receptor antagonists, which represent a well‐established cornerstone and life‐saving therapy.